Clinical trial
Staccato Fentanyl Single and Multidose PK
NCT00402350 · Alexza Pharmaceuticals, Inc., Other · Completed
Key facts
| NCT number | NCT00402350 |
|---|---|
| Title | Staccato Fentanyl Single and Multidose PK |
| Official title | Safety, Tolerability, and Pharmacokinetics of Staccato® Fentanyl for Inhalation in Normal, Healthy Volunteers |
| Lead sponsor | Alexza Pharmaceuticals, Inc., Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breakthrough Pain |
| Intervention type | Drug |
| Interventions | Inhaled Placebo, Inhaled Fentanyl 25 mcg, Intravenous Fentanyl 25 mcg, Inhaled Fentanyl 25 mcg x 2, Inhaled Fentanyl 25 mcg x 4, Inhaled Fentanyl 25 mcg x 6, Inhaled Fentanyl 25 mcg x 12 |
| Enrollment | 51 |
| Start date | Apr 1, 2006 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Nov 22, 2006 |
| Last update posted | Mar 15, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: